A series of market to market forums initiated by CREW UK connecting London with Toronto, Berlin, New York, Singapore and India continues. This time, the conversation will focus on the expanding life sciences sector in the UK. What does the business of life sciences include and what does it require in terms of real estate? What volume of real estate development work was in-flight pre-pandemic and what is the forecast for the future?
According to the BioIndustry Association (BIA), life sciences has seen UK investment reach a record £2.8 billion in 2020 and new data from BIA and Clarivate shows that the UK’s biotech and life sciences sector is on the cusp of a golden age driven by strong demand from global investors for UK innovation, with £1.56bn invested in the last quarter (March 2021 – May 2021).
The UK’s ‘Golden Triangle’ of London, Oxford and Cambridge is, not only competing internationally, it’s a major growth area for UK real estate including projects for technology, life sciences, research and development companies. Per Deloitte’s 2020 Global life sciences outlook
, the increased adoption of new technologies like telemedicine, virtual clinical trials, and AI could increase access to medical research and expand diversity.
Please join CREW UK and life science experts from GlaxoSmithKline and JLL to gain business insights and learn about potential new real estate trends, innovations and challenges.
Senior Director, The Instant Group
CREW UK Board Member
Director Life Science + Project Management at JLL
CREW UK Member
Global Portfolio Strategy Director, GSK